Joseph A. Tyndall sold $778k of AXGN
director at Axogen, Inc.. 25,108 shares at an average of $30.98, traded Dec 9, 2025, filed Dec 10, 2025.
Score components
- +15RoleDirector
- +22Trade size$778k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster10 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +11.7%, 3m +7.6%, 6m +37.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000805928-25-000166, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2025 | MOption exercise Common Stock | +14,248 | $7.04 | $100k | 14,248 | Dec 10, 2025 |
| Dec 9, 2025 | MOption exercise Common Stock | +10,860 | $10.95 | $119k | 25,108 | Dec 10, 2025 |
| Dec 9, 2025 | SOpen-market sale Common Stock | -14,248 | $30.98 | $441k | 10,860 | Dec 10, 2025 |
| Dec 9, 2025 | SOpen-market sale Common Stock | -10,860 | $30.98 | $336k | 0 | Dec 10, 2025 |
| Dec 9, 2025 | MOption exercise Employee Stock Option (right to purchase)derivative | -14,248 | $0.00 | $0 | 0 | Dec 10, 2025 |
| Dec 9, 2025 | MOption exercise Stock Option (right to purchase)derivative | -10,860 | $0.00 | $0 | 32,311 | Dec 10, 2025 |
Related signals
Other insiders at Axogen, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Axogen, Inc. | Joseph A. Tyndall director | $174k 3,500 shares | -25% | |
| 20Weak | Axogen, Inc. | Amy McBride Wendell director | $647k 13,353 shares | -11% | |
| 40Moderate | Axogen, Inc. | Marc A Began EVP & General Counsel | $3.2M 67,500 shares | -57% | |
| 50Moderate | Axogen, Inc. | Kathy Johnson Weiler director | $641k 14,150 shares | -100% | |
| 23Weak | Axogen, Inc. | Amy McBride Wendell director | $70k 1,647 shares | -2% | |
| 41Moderate | Axogen, Inc. | Doris Quackenbush Sales VP | $169k 3,878 shares | -4% | |
| 28Weak | Axogen, Inc. | Lindsey Marie Hartley CFO | $46k 1,051 shares | -2% | |
| 41Moderate | Axogen, Inc. | Jens Kemp Chief Marketing Officer | $174k 4,000 shares | -5% | |
| 56Moderate | Axogen, Inc. | Kathy Johnson Weiler director | $721k 16,344 shares | -100% | |
| 53Moderate | Axogen, Inc. | John Johnson director | $478k 11,050 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.